Last edition
News about "post void residual (PVR)"
Medicus Pharma Submits Phase 2 Protocol to US FDA for Teverelix in Acute Urinary Retention
Medicus Pharma submits Phase 2 protocol to US FDA for Teverelix in acute urinary retention, targeting a USD 2 billion market with a mechanism-driven, capital-efficient development strategy.
Post Void Residual (PVR) | 07/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members